SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 30, 2003
OCULAR SCIENCES, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-22623 94-2985696
--------------- --------------- ---------------
(State or Other Jurisdiction of
Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
1855 GATEWAY BOULEVARD, SUITE 700
CONCORD, CALIFORNIA 94520
(Address of Principal Executive Offices)
--------------------
(925) 969-7000
(Registrant's telephone number, including area code)
--------------------
ITEMS 9 AND 12. REGULATION FD DISCLOSURE AND DISCLOSURE OF RESULTS OF OPERATIONS
AND FINANCIAL CONDITION.
The information in this Report, including the Exhibit 99.1 attached
hereto, is furnished pursuant to Items 9 and 12 of this Form 8-K. Consequently,
it is not deemed "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, or otherwise subject to the liabilities of that Section.
It may only be incorporated by reference in another filing under the Securities
Exchange Act of 1934 or Securities Act of 1933 if such subsequent filing
specifically references this Form 8-K.
On July 30, 2003, Ocular Sciences, Inc. (the "Company") announced its
results of operations and financial condition as of and for the second quarter
ended June 30, 2003 in a press release that is attached hereto as Exhibit 99.1.
The Company's earnings release contains non-GAAP financial measures.
Pursuant to the requirements of Regulation G, the Company has provided
reconciliations within the press release of the non-GAAP financial measures to
the most directly comparable GAAP financial measures.
Adjusted net income and earnings per share data is presented in the
earnings release. The net income and earnings per share data is adjusted to
exclude restructuring charges that impacted the Company's results of operations.
Specifically, the Company has excluded restructuring charges associated with the
manufacturing transition program announced in December 2002 that the Company
expects to complete in 2004. The Company's management uses this information
excluding these charges in evaluating results of the continuing operations of
the Company and believes that this information provides investors with valuable
insight into the underlying results of operations of the Company and facilitates
comparison between the Company and other companies.
Exhibits
The following exhibit is furnished as part of this Report:
No. Exhibit
--- -------
99.1 Press Release dated July 30, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: July 30, 2003
OCULAR SCIENCES, INC.
By: /s/ Seth Halio
------------------------------
Seth Halio
Controller